Forward Therapeutics

FL - Palm Beach GardensBiotechnology2 H-1B visas (FY2023)

Focus: Forward Therapeutics is a small-stage biotech focused on oral agents for inflammatory conditions, primarily in immunology. With 1-50 employees and no public revenue data, the company is in early-to-mid development stage.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Employees

1-50

Total Funding

$58M

Open Jobs

About Forward Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Forward Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Guaranteed Income

Early Child Well-being

N/A

Clinical Trials (1)

NCT06505811Mixed Methods Evaluation of the Pomona Household Universal Grant (HUG) Program

N/A

Help build intelligence for Forward Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead role potential: With only 1-50 employees, you can shape drug development strategy and own significant project responsibility early in your career.
Focused pipeline in high-value area: Immunology/inflammatory diseases represent a large market with multiple shots on goal (FP187 in Phase 3 for psoriasis).
Demonstrates visa sponsorship: 2 H1B approvals with 0 denials in 2023 shows willingness to recruit diverse talent.

Watch Out For

Zero current job openings and undisclosed funding create uncertainty about runway and near-term hiring capacity.
Data quality issues in pipeline (e.g., entries for 'Placebo' and 'Guaranteed Income') suggest early-stage operational immaturity or data management gaps.
No commercialized products, no revenue, and minimal clinical progress (only 1 Phase 3 program) mean no near-term value inflection events.

Generated by Claude from Forward Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

FWD1802

Healthy

Phase 1

Clinical Trials (1)

NCT07476963Evaluation of the Food Effecton the Pharmacokinetics of FWD1802 in Healthy Subjects

Phase 1

FWD1802

Metastatic Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT06064812A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

Phase 1/2